Valneva SE
LB6V
Lyme disease
Resolved
106days ago
Phase 3 readout · Mar 23, 2026
What's at stake
Phase 3 trial results for LB6V in Lyme disease are due Mar 23, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“LB6V demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above.”